Trial details
CROSS- CRPC Oligometastases treated with SBRT plus Systemic therapy
To find out more about this trial and your cancer treatment options, please speak with your doctor.
Trial short name: CROSS
Official title: CROSS- CRPC Oligometastases treated with SBRT plus Systemic therapy
Principal Investigator: Dr. Jay Detsky
Cancer type: Genitourinary
Cancer location: Prostate
Disease stage: Early Cancer
Trial phase:
Intervention:
Registration #:
Contact e-mail: cancerclinicaltrials@sunnybrook.ca
Inclusion criteria: 1. Age > 18 years. 2. Able to provide informed consent. 3. Histologic diagnosis of prostate adenocarcinoma. 4. ECOG performance status 0-1. 5. Castrate resistant metachronous oligometastatic prostate cancer as detected by PSMA PET-CT scan with either a) no metastases visible on conventional imaging (CT chest/abdomen/pelvis and bone scan +/- MRI) performed within 3 months of study entry, or b) equivocal metastases on conventional imaging. 6. CRPC defined as three rising PSA levels with an interval of >1 week between each measurement in the setting of castrate testosterone levels (serum testosterone level <1.7 nmol/L or <50 ng/dL) 7. PSA of >1.0 ng/mL 8. Up to a maximum of 5 PSMA avid areas of metastatic disease. 9. Ongoing androgen deprivation therapy with a GnRH analog or bilateral orchiectomy 10. All sites of disease are amenable to and can be safely treated with radiotherapy. Exclusion criteria: 1. Significant comorbidities rendering patient not suitable for ADT and/or ARAT and/or SBRT. 2. History of malignancy within the past 5 years, excluding non-melanoma skin cancer and in-situ cancer. 3. Prior use of systemic therapy (outside of androgen deprivation therapy) for CRPC >3 months. 4. Evidence of spinal cord compression.
